NASDAQ:SCLX Scilex Q3 2025 Earnings Results & Report $2.95 +0.07 (+2.47%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more. Scilex missed analyst expectations on both earnings and revenue in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$22.17 versus the -$0.41 consensus estimate, while revenue of $10.56 million fell short of the $26.25 million estimate by $15.69 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 14, 2025TimeBefore Market OpensConference Call7:00 AM ET Scilex EPS ResultsActual EPS-$22.17Consensus EPS -$0.41Beat/MissMissed by -$21.76One Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersScilex Revenue ResultsActual Revenue$10.56 millionExpected Revenue$26.25 millionBeat/MissMissed by -$15.69 millionYoY Revenue GrowthN/AUpcoming EarningsScilex's Q3 2026 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Scilex Q3 2025 Earnings FAQ Did Scilex beat earnings estimates for Q3 2025? Scilex (NASDAQ:SCLX) reported earnings of -$22.17 per share for Q3 2025, missing the consensus estimate of -$0.41. The report was announced on Friday, November 14, 2025. What was Scilex's revenue for Q3 2025? Scilex reported revenue of $10.56 million for Q3 2025, against a consensus estimate of $26.25 million. When is Scilex's next earnings date? Scilex's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Scilex on the company's earnings history page. Scilex Earnings HeadlinesCritical Survey: Enanta Pharmaceuticals (NASDAQ:ENTA) & Scilex (NASDAQ:SCLX)October 13 at 4:17 AM | americanbankingnews.comScilex (NASDAQ:SCLX) versus Sanofi (NASDAQ:SNY) Critical ReviewOctober 11 at 8:15 AM | americanbankingnews.comThe Midwestern Disruptor Big Pharma Doesn’t Want You to Know AboutA little-known Midwestern firm sits at the center of what the Wall Street Journal calls medicine's biggest moment since antibiotics. It does not invent drugs or hold blockbuster patents. McKinsey calls the shift a game changer, and the International Journal of Surgery describes it as a revolutionary path forward. Yet this company remains largely overlooked by investors. See the full research on this emerging healthcare story now.October 14 at 1:00 AM | Compounding Quality (Ad)Scilex Expands Credit Facility Support for Vivasor AffiliateSeptember 29, 2026 | tipranks.comScilex Establishes $20 Million Credit Facility for VivasorAugust 12, 2026 | tipranks.comScilex Announces Strategic Sale of Vivasor Preferred SharesJuly 22, 2026 | tipranks.comSee More Scilex Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email. Email Address About ScilexScilex (NASDAQ:SCLX) is a commercial-stage pharmaceutical company focused on developing and commercializing non-opioid and specialty prescription treatments for acute and chronic pain. The company’s portfolio includes products designed to address conditions such as postherpetic neuralgia, acute migraine, and gout flares. Scilex markets ZTlido (lidocaine topical system) in the United States for the relief of pain associated with postherpetic neuralgia. Its portfolio also includes Elyxyb, an oral solution indicated for the acute treatment of migraine with or without aura in adults, and Gloperba, an oral liquid formulation of colchicine used to prevent and treat gout flares in adults. The company is also developing SP-102, an investigational, sustained-release corticosteroid injection intended to treat lumbosacral radicular pain, commonly known as sciatica. SP-102 remains subject to clinical development and regulatory review, and its future availability is not assured. Scilex is headquartered in the United States and focuses primarily on the U.S. specialty pharmaceutical market. Jaisim Shah serves as the company’s chief executive officer.View Scilex ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
